Silvia Naomi de Oliveira Uehara

Silvia Naomi de Oliveira Uehara

Auto-generated profile, based on publicly available information

Silvia Naomi de Oliveira Uehara

Universidade Federal de Mato Grosso do Sul, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
Larissa Melo BandeiraLarissa Melo Bandeira
Larissa Melo Bandeira
MPMarco Antonio Moreira Puga
Marco Antonio Moreira Puga
SWSabrina Weis-Torres
Sabrina Weis-Torres
GRGrazielli R. Rezende
Grazielli R. Rezende
JDJoão A. Domingos
João A. Domingos
ACAna Rita Coimbra Coimbra Motta de Castro
Ana Rita Coimbra Coimbra Motta de Castro
Human T-cell leukemia virus type 1 (HTLV-1) has worldwide distribution and is considered endemic in southwestern Japan. HTLV-1 infection has been associated with adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) besides other diseases. This cross-sectional study aimed to investigate the prevalence, risk factors and molecular characterization of HTLV-1, among the world’s largest population of Japanese immigrants and their descendants outside of Japan, in São Paulo, Southeast Brazil, as well as to analyze the phylogenetic relationship among isolates of HTLV-1. From July to December 2017, 2,139 individuals from five Japanese associations were interviewed and submitted to blood collection. All serum samples were first tested for the presence of anti-HTLV-1/2 antibodies by ELISA and then peripheral blood from individuals with positive serological results were analyzed for the presence of HTLV-1 5’LTR proviral DNA. Partial sequencing of the 5’LTR region of HTLV-1 proviral DNA was performed by Sanger. The prevalence of HTLV-1 infection was 5.1% (CI 95%: 4.2–6.0). In the multiple logistic regression model, HTLV-1 infection was associated with age ≥ 45 years, female sex, being first and second-generation Japanese immigrants, and having sexual partners with history of blood transfusion. The phylogenetic analysis revealed that all HTLV-1 were classified as Cosmopolitan (1a) subtype. Of them, 47.8% were classified as Transcontinental (A) subgroup and 52.2% as belonging to the Japanese (B) subgroup. Although most HTLV-1-infected patients were asymptomatic (97.3%), blurred vision was associated with HTLV-1 infection. The high prevalence of HTLV-1 infection found in this studied population and especially the intra- and interfamily HTLV-1 transmission presents an urgent call for preventive and control responses of this infection in Brazil.

23 March 2020 in Journal of Applied Microbiology
Verified
Journal Article
Open access
PDF file
Larissa Melo BandeiraLarissa Melo Bandeira
Larissa Melo Bandeira
MPMarco Antonio Moreira Puga
Marco Antonio Moreira Puga
VPVanessa de Paula
Vanessa de Paula
Luiz Henrique Ferraz DemarchiLuiz Henrique Ferraz Demarchi
Luiz Henrique Ferraz Demarchi
GLGislene Garcia de Castro Lichs
Gislene Garcia de Castro Lichs
ACAna Rita Coimbra Coimbra Motta de Castro
Ana Rita Coimbra Coimbra Motta de Castro
Aims To evaluate the potential use of synthetic oligonucleotides as a standard curve for proviral load (PVL) of HTLV‐1 quantification in peripheral blood mononuclear cells (PBMC) of HTLV‐1‐infected individuals by qPCR analysis. Methods and results Synthetic oligonucleotides based on HTLV‐1 genome were customized to use as a standard curve. Twelve anti‐HTLV‐1 positive samples with known HTLV‐1 PVL, previously quantified by qPCR assay using TARL‐2 cells as a conventional standard curve, were submitted to the new protocol. The proviral quantification levels had a high concordance with qPCR results using a conventional standard curve. The results demonstrate that the conventional standard curve can be replaced by a synthetic standard curve due to its ability to quantification based on the linearity and qPCR efficiency and similar results with a validated qPCR assay using a conventional standard curve. Conclusions Synthetic oligonucleotides standard curves could be a very useful tool on HTLV‐1 diagnosis and absolute HTLV‐1 PVL quantification. Significance and impact of study HTLV‐1 PVL determination using synthetic oligonucleotides standard curve by qPCR could be a helpful alternative for the laboratories that monitor infected patients as an important prognostic factor in HTLV‐1 associated diseases progression. Also, it can decrease costs and overcome the biological limitations of the plasmid curve.

18 June 2025 in Journal of Medical Virology
Verified
Journal Article
Open access
KOKetty Gleyzer de Oliveira
Ketty Gleyzer de Oliveira
MVMariana Pinheiro Alves Vasconcelos
Mariana Pinheiro Alves Vasconcelos
JTJulia Teixeira Ton
Julia Teixeira Ton
SUSilvia Naomi de Oliveira Uehara
Silvia Naomi de Oliveira Uehara
RSRoberta Sitnik
Roberta Sitnik
João Renato Rebello PinhoJoão Renato Rebello Pinho
João Renato Rebello Pinho
Hepatitis A Virus (HAV) infects millions of individuals annually and is a major cause of acute viral hepatitis worldwide. This study aims to (1) assess HAV infection in suspected acute hepatitis patients at public healthcare institutions in Brazil; (2) evaluate the proportion of immunized individuals against HAV; (3) identify HAV genotypes; (4) examine the association between HAV infection and demographic data, as well as exposure to risk factors. This is a prospective, observational multicenter study conducted in primary health services in Brazil from October 2019 to May 2023, involving 1721 patients with suspected acute hepatitis. Acute HAV infection was identified in 108 (6.3%) patients, predominantly in young men (80%) and from South and Southeast regions of Brazil (97%). Anti‐HAV IgG, indicating previous exposure or vaccination, was detected in 78.6% of individuals (74% in the South to 91% in the North). Genotype I.A was found in all cases and approximately 450 mutations were identified, most of them in the structural proteins VP1‐3. Two viral groups were identified and related to two introductions of the virus: cosmopolitan sequences from North America, South America, and Europe, and a minor group of Brazilian sequences similar to Asian and South American ones. The high incidence of acute HAV infections highlights the need for targeted prevention and vaccination strategies. The characterization of HAV genetic diversity and molecular epidemiology contributes to monitoring and identifying emerging outbreaks.

1 January 2026 in Brazilian Journal of Nephrology
Verified
Journal Article
Open access
PAPatrícia Ferreira Abreu
Patrícia Ferreira Abreu
PAPablo Rodrigues Costa Alves
Pablo Rodrigues Costa Alves
PBPaulo Lisboa Bittencourt
Paulo Lisboa Bittencourt
ICIsadora Cartaxo de Sousa Calvo
Isadora Cartaxo de Sousa Calvo
ONOsvaldo Merege Vieira Neto
Osvaldo Merege Vieira Neto
MFMaria Lucia Gomes Ferraz
Maria Lucia Gomes Ferraz
Resumo Introdução: A infecção pelo vírus da hepatite C (HCV) é um desafio de saúde pública, especialmente em pacientes em diálise, que apresentam maior vulnerabilidade e risco de transmissão. A estratégia de microeliminação em subgrupos de alto risco é fundamental para atingir as metas globais da Organização Mundial da Saúde. Métodos: Trata-se de um estudo nacional de implementação, multicêntrico e prospectivo, fundamentado no Registro Brasileiro para Eliminação da Hepatite C em Unidades de Diálise. As 904 unidades de diálise ativas do país foram convidadas; 384 (42,5%) aderiram voluntariamente e, em cada uma, todos os pacientes elegíveis foram arrolados entre 2021 e 2024. Avaliou-se a cascata de cuidado: rastreamento sorológico (anti-HCV), confirmação virológica (RNA-HCV), tratamento com antivirais de ação direta (DAAs) e resposta virológica sustentada (SVR). Resultados: Foram avaliados 66.601 pacientes, com prevalência nacional de anti-HCV de 2,08%. A cobertura de testagem para RNA-HCV foi de 65,4%, com positividade de 64,2% entre os testados, resultando em uma prevalência ajustada de viremia de 1,34%. Dos pacientes com viremia detectada, 74,2% iniciaram o tratamento, 92,6% completaram o esquema e 93,3% alcançaram a SVR. As principais barreiras incluíram indisponibilidade de exames e óbito. Discussão: Os resultados demonstram que o Brasil possui indicadores robustos de eficácia terapêutica, situando o país em estágio avançado para a eliminação do HCV na população dialítica. No entanto, persistem gargalos operacionais na confirmação diagnóstica. Conclusão: A eliminação do HCV em unidades de diálise é uma meta factível no Brasil. O sucesso depende da manutenção do rastreio universal, do tratamento imediato dos casos confirmados e da integração contínua entre a nefrologia e a hepatologia.

1 January 2024 in Arquivos de Gastroenterologia
Verified
Journal Article
Open access
PDF file
JXJoão Batista Xavier
João Batista Xavier
JSJoel Schmillevitch
Joel Schmillevitch
CEChristini Emori
Christini Emori
SUSilvia Uehara
Silvia Uehara
ENEunice Jadriana Nunes
Eunice Jadriana Nunes
MFMaria Lucia Ferraz
Maria Lucia Ferraz
Background: Liver biopsy (LB) is still the gold standard method for assessing hepatic fibrosis (HF), associated diseases, and liver inflammation. Nowadays, noninvasive techniques such as Acoustic radiation force impulse (ARFI) elastography have been introduced instead of liver biopsy. However, there are controversies about the time it should be performed after treatment for hepatitis C virus (HCV).

1 January 2026 in Brazilian Journal of Nephrology
Verified
Journal Article
Open access
PAPatrícia Ferreira Abreu
Patrícia Ferreira Abreu
PAPablo Rodrigues Costa Alves
Pablo Rodrigues Costa Alves
PBPaulo Lisboa Bittencourt
Paulo Lisboa Bittencourt
ICIsadora Cartaxo de Sousa Calvo
Isadora Cartaxo de Sousa Calvo
ONOsvaldo Merege Vieira Neto
Osvaldo Merege Vieira Neto
MFMaria Lucia Gomes Ferraz
Maria Lucia Gomes Ferraz
Introduction: Hepatitis C virus (HCV) infection remains a major public health challenge, particularly among patients undergoing dialysis, who are disproportionately vulnerable and at increased risk of transmission. Micro-elimination strategies targeting high-risk subpopulations are a critical component for achieving the World Health Organization global HCV elimination goals. Methods: This national, multicenter, prospective implementation study was conducted within the framework of the Brazilian Registry for the Elimination of HCV in Dialysis Units. All 904 active dialysis units in the country were invited; 384 (42.5%) joined voluntarily, and, within each, all eligible patients were enrolled (census) between 2021 and 2024. The HCV cascade of care was evaluated, including serological screening (anti-HCV), virological confirmation (HCV-RNA), treatment with direct-acting antivirals (DAAs), and assessment of sustained virologic response (SVR). Results: A total of 66,601 patients were evaluated, yielding a national anti-HCV prevalence of 2.08%. HCV-RNA testing coverage reached 65.4%, with a positivity rate of 64.2% among those tested, resulting in an adjusted prevalence of active viremia of 1.34%. Among patients with detectable viremia, 74.2% initiated antiviral therapy, 92.6% completed treatment, and 93.3% achieved SVR. The main barriers identified along the cascade of care included limited availability of diagnostic tests and patient mortality. Discussion: These findings indicate that Brazil has achieved robust therapeutic effectiveness indicators, placing the country at an advanced stage toward HCV elimination within the dialysis population. Nonetheless, important operational gaps persist, particularly in diagnostic confirmation. Conclusion: Elimination of HCV in dialysis units is an achievable goal in Brazil. Sustained success depends on maintaining universal screening, ensuring prompt treatment initiation for confirmed cases, and strengthening continuous integration between services.